RRC ID 36972
Author Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.
Title Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Journal Leuk Res
Abstract We introduced SNX2-ABL1, a novel ABL1-related chimeric transcript lacks SH3 and SH2 domains, into murine Ba/F3 cells and compared their function with that of BCR-ABL1. After the expression of SNX2-ABL1 proteins, Ba/F3 cells acquired an ability to proliferate in an IL-3-independent manner. Upon treatment with both imatinib and dasatinib, BCR-ABL1-expressing Ba/F3 cells underwent rapid apoptosis, whereas SNX2-ABL1-expressing Ba/F3 cells showed poorer sensitivity toward these TKIs and could proliferate in the presence of a low dose of dasatinib. Therefore, other TKIs with a more selective effect against this chimeric kinase should be used for the treatment of patients with SNX2-ABL1+ ALL.
Volume 38(3)
Pages 361-70
Published 2014-3-1
DOI 10.1016/j.leukres.2013.11.017
PII S0145-2126(13)00418-9
PMID 24367893
MeSH Animals B-Lymphocytes / drug effects* B-Lymphocytes / immunology B-Lymphocytes / pathology Benzamides / pharmacology Cell Line Dasatinib Dose-Response Relationship, Drug Drug Resistance, Neoplasm Fusion Proteins, bcr-abl / genetics* Fusion Proteins, bcr-abl / immunology Gene Expression Regulation, Leukemic / drug effects* Genetic Vectors Humans Imatinib Mesylate Interleukin-3 / pharmacology Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology Mice Piperazines / pharmacology Protein Kinase Inhibitors / pharmacology* Protein Structure, Tertiary Pyrimidines / pharmacology Retroviridae / genetics Sorting Nexins / genetics* Sorting Nexins / immunology Thiazoles / pharmacology Transfection
IF 2.214
Times Cited 13
Human and Animal Cells WEHI-3(RCB0035)